IL301500A - TREATMENT OF NF-κB-MEDIATED DISEASE - Google Patents

TREATMENT OF NF-κB-MEDIATED DISEASE

Info

Publication number
IL301500A
IL301500A IL301500A IL30150023A IL301500A IL 301500 A IL301500 A IL 301500A IL 301500 A IL301500 A IL 301500A IL 30150023 A IL30150023 A IL 30150023A IL 301500 A IL301500 A IL 301500A
Authority
IL
Israel
Prior art keywords
day
human patient
vamorolone
muscular dystrophy
participants
Prior art date
Application number
IL301500A
Other languages
English (en)
Hebrew (he)
Inventor
DAMSKER Jesse
Hoffman Eric
Original Assignee
Reveragen Biopharma Inc
DAMSKER Jesse
Hoffman Eric
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reveragen Biopharma Inc, DAMSKER Jesse, Hoffman Eric filed Critical Reveragen Biopharma Inc
Publication of IL301500A publication Critical patent/IL301500A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL301500A 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE IL301500A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US202163214908P 2021-06-25 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (1)

Publication Number Publication Date
IL301500A true IL301500A (en) 2023-05-01

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301500A IL301500A (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Country Status (9)

Country Link
US (2) US20220184098A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213855A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543439A (cg-RX-API-DMAC10.html)
KR (1) KR20230092905A (cg-RX-API-DMAC10.html)
AU (1) AU2021343534A1 (cg-RX-API-DMAC10.html)
CA (1) CA3170698A1 (cg-RX-API-DMAC10.html)
IL (1) IL301500A (cg-RX-API-DMAC10.html)
MX (1) MX2023003258A (cg-RX-API-DMAC10.html)
WO (1) WO2022061287A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2785351A4 (en) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc NONTHORMONAL STEROID MODULATORS OF NF-KB FOR THE TREATMENT OF DISEASES
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
US11382922B2 (en) * 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
AU2021343534A1 (en) 2023-05-11
MX2023003258A (es) 2023-05-08
US20220184098A1 (en) 2022-06-16
EP4213855A4 (en) 2024-10-23
EP4213855A1 (en) 2023-07-26
US20240139210A1 (en) 2024-05-02
WO2022061287A1 (en) 2022-03-24
CA3170698A1 (en) 2022-03-24
KR20230092905A (ko) 2023-06-26
JP2023543439A (ja) 2023-10-16

Similar Documents

Publication Publication Date Title
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US20240139210A1 (en) Treatment of nf-kb-mediated disease
JP2024097878A (ja) 結晶性19-ノルc3,3-二置換c21-n-ピラゾリルステロイド
JP7819094B2 (ja) ヒトアミノステロールent-03化合物、それを含む関連組成物、およびそれを使用する方法
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
US20240299416A1 (en) TREATMENT OF NF-kB-MEDIATED DISEASE
AU2021329312A1 (en) Pharmaceutical composition containing neuroactive steroid and use thereof
JP2016510343A (ja) ラキニモドを用いる多発性硬化症の治療
AU2024204716A1 (en) Treatment of alopecia areata
US20240226117A1 (en) Treatment of congenital adrenal hypoplasia
AU2019386235B2 (en) Montelukast for the treatment of erosive hand osteoarthritis
CN116507338A (zh) NF-κB介导的疾病的治疗
WO2021188148A1 (en) Crystalline forms of squalamine
WO2026092580A1 (en) Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
EP4470563A1 (en) New therapy and prevention for suppressing aging-related disorders including sarcopenia
RU2776845C2 (ru) Аналоги целастрола
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
BRPI0916241B1 (pt) Formulação farmaucêutica contendo ligantes de receptores de dopamina e seu uso